Bio101

BIO101: Our drug candidate is an oral small molecule potential
for best in class acting on the root cause of muscle wasting

BIO101: Our drug candidate is an oral small molecule potential for best in class acting on the root cause of muscle wasting

First in class molecule:

  • Validated mechanism of action
  • Activation of MAS receptor (protective arm of the renin-angiotensin system)
  • Regulation of smooth, cardiac and skeletal muscle metabolism

Excellent safety profile:

  • More than 275 patients exposed to BIO101 in clinical trials
  • No major adverse event observed

Ease of administration:

  • API manufactured at industrial scale
  • Advanced CMC
  • Oral capsules adapted to chronic conditions

Focused development program for improving mobility

Indication

Program

Discovery

Lead Op

IND Enabling

Phase 1

Phase 2

Phase 3

Registration

Sarcopenia

SARA

Obesity

OBA

Indication

Program

Discovery

Lead
Op

IND Enabling

Ph. 1

Ph. 2

Ph. 3

Registration

Sarcopenia

SARA

Obesity

OBA

Program

Discovery

Lead Op

IND Enabling

Phase 1

Phase 2

Phase 3

Registration

Sarcopenia

SARA

Obesity

OBA